To compare patterns of acute and late clinical/radiological lung toxicity following either 3D or image-guided VMAT stereotactic radiotherapy for stage I nonsmall cell lung cancer (NSCLC).
Results:
Patients and tumors' characteristics were similar and well matched between the groups. PTV volumes were also comparable (35.1 cc for 3D-CRT vs. 40.3 cc for VMAT,, p=0.16). Moreover, no significant difference was detected in Mean Lung Dose, converted in 2 Gy equivalent (11.7 vs. 10.4 Gy for 3D-CRT and VMAT, respectively, p=0.13). Frequencies of acute and late clinical toxicity (all grades) were superimposable between 3D-CRT and VMAT (acute: 10.5% vs. 22.6%, p=0.28; late: 4.2% vs. 13%, p=0.09, respectively). The crude rate of RTOG acute ≥ grade 3 radiation pneumon itis was 2.1% after 3D-CRT and 3.8% after VMAT. Acute and late radiological toxicity patterns were also similar between the two cohorts. Figures 1 and 2 depict the incidence and grade of both, according to different treatments. As expected, late radiological toxicity occurred in approximately 60% of patients, with modified conventional (25% after 3D-CRT vs. 32.6% after VMAT) and mass-like (19.6% after 3D-CRT vs. 17.4% after VMAT) patterns as the most commonly observed findings.
Conclusion:
Results of the present study indicate that the pattern of clinical and radiological toxicities following SBRT in peripheral early stage NSCLC treated with comparable BED10Gy is not influenced by the different techniques used for planning and delivery.
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Non-small cell lung cancer: marked difference in first failure site depending on histology L. Nygaard being most frequent. The prognosis is poor with current chemo-radiation strategies and treatment intensification is limited by patient tolerance. It is therefore relevant to target experimental therapeutic approaches to a patient's risk of local versus distant failure. The purpose of the current study was to compare the pattern of first relapse after chemoradiation for locally advanced pulmonary SCC and AC.
Material and Methods:
We retrospectively included 193 patients with locally advanced NSCLC treated with chemoradiotherapy from 2009 to 2012. Patients with initial stage IV (n= 17) disease and/or patients with histology other than AC or SCC (n= 22) were excluded leaving 155 patient for the analysis. Patients were identified and grouped according to first event as either: loco-regional (LR) failure; intra-cranial distant metastases (ICDM), extra-cranial distant metastases (ECDM); dead without evidence of disease (Dead, NED), with the remaining patients being Alive, NED at latest follow-up in August 2015. The cumulative incidence of events was compared across the histology subtypes, using the competing risk method of Fine and Gray.
Results:
Patients received sequential (n = 49, 32%) or concomitant (n = 93, 60%) chemo-radiotherapy. Eleven patients received radiotherapy alone.. Competing risks analysis found a significantly higher rate of ICDM in the AC group compared to SCC (p= 0.0004) but no significant difference in incidence of ECDM (p= 0.08). LR failure was higher in SCC than in AC (p= 0.01). There was no significant difference between the two histology groups in the proportion dying without evidence of disease (p= 0.3), see Figure. Restricting the analysis to patients with distant metastases as first site of failure, there was a significantly higher rate of cerebral metastases in AC than in SCC (p= 0.04), cf. Table 1 .
Conclusion:
The pattern of first failure in inoperable NSCLC differs among patients with AC and SCC with intra-cranial distant metastases being more common in AC than in SCC and LR relapse being much more frequent in SCC than in AC. Experimental treatment strategies should be targeting different relapse patters in various histological subtypes. Intensification of local therapy for example may yield a worse risk/benefit ratio in AC compared to SCC. 
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